Evidence map›Paper›PMID 37340305›Full record

ArticleClinical genetics2023

Medical and psychosocial outcomes of state-funded population genomic screening.

Ashley Cannon, Olivia McMillan, Whitley V Kelley, Kelly M East, Meagan E Cochran, Edrika L Miskell, Irene P Moss, Sherilyn Garner-Duckworth, David T Redden, Matthew Might and 2 more

Abstract read
In one paragraph

Article in Clinical genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ashley CannonHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Olivia McMillanSchool of Health Professions, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Whitley V KelleyHudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA.
Kelly M EastHudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA.
Meagan E CochranHudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA.
Edrika L MiskellHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Irene P MossHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sherilyn Garner-DuckworthSchool of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
David T ReddenDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Matthew MightHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Gregory S BarshHudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA.
Bruce R KorfHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Funding

National Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6M
NCATS NIH HHS UL1 TR003096
6 · The paper itself

Abstract

As the uptake of population screening expands, assessment of medical and psychosocial outcomes is needed. Through the Alabama Genomic Health Initiative (AGHI), a state-funded genomic research program, individuals received screening for pathogenic or likely pathogenic variants in 59 actionable genes via genotyping. Of the 3874 eligible participants that received screening results, 858 (22%) responded to an outcomes survey. The most commonly reported motivation for seeking testing through AGHI was contribution to genetic research (64%). Participants with positive results reported a higher median number of planned actions (median = 5) due to AGHI results as compared to negative results (median = 3). Interviews were conducted with survey participants with positive screening results. As determined by certified genetic counselors, 50% of interviewees took appropriate medical action based on their result. There were no negative or harmful actions taken. These findings indicate population genomic screening of an unselected adult population is feasible, is not harmful, and may have positive outcomes on participants now and in the future; however, further research is needed in order to assess clinical utility.

Indexed as

GenomicsMetagenomicsAdultGenetic TestingHumansgenetic testinggenomicsmass screeningpatient outcome assessmentpopulation health

Identifiers

PMID37340305
PMCPMC11299714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.